There is one clinical trial.
The purpose of this study is to determine if the use of inhaled beclomethasone after a
community-acquired respiratory viral infection in a lung transplant recipient decreases the
risk of the subsequent development of chronic lung allograft dysfunction.
Primary Outcomes
Measure: Freedom from new or progressive chronic lung allograft dysfunction Time: 180 days
Measure: Death Time: 180 days
Secondary Outcomes
Measure: Respiratory virus symptom score Time: 7 days
Measure: Acute rejection Time: 180 days
Measure: Lymphocytic bronchiolitis Time: 180 days
Measure: Donor-specific antibodies Time: 180 days
Measure: Chronic lung allograft dysfunction Time: 365 days